Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Nov 10, 2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.
Read more at globenewswire.com
